Goodluck Lyatuu

Goodluck Lyatuu

Affiliated to Research
Visiting address: Widerströmska huset Tomtebodavägen 18 A, plan 3, 17165 Solna
Postal address: K9 Global folkhälsa, K9 GPH Ekström, 171 77 Stockholm

About me

  • I am a medical doctor and public health specialist at Management and
    Development for Health (MDH) in Dar es Salaam, Tanzania. For the most of my
    career, my work has mainly centered on reproductive, maternal, newborn and
    child health (RMNCH) and Infectious Diseases. These two areas remain among
    major health challenges in sub-Saharan Africa (SSA) and many other developing
    countries. My career motivation is to lead efforts, build networks and
    collaborate to bridge the gap in research, practice and health outcomes by
    generating, sharing and applying scientific evidence to address health
    challenges in Tanzania, SSA and the world at large. As a PhD candidate at KI,
    my research is focused on investigating the effect of the World Health
    Organization (WHO)'s Option B+ intervention in the prevention of mother to
    child transmission of HIV (PMTCT) in routine care settings. (more information
    Henry Masters Award –The Dartmouth Institute, For exemplifying Henry’s
    spirit and passion, for continuing Henry’s bright light full of passion,
    intelligence and compassion, and for caring deeply about making a difference
    in health care through social change, Dartmouth College, Hanover, NH
    Research Capstone Award - The Dartmouth Institute, For exemplary achievement
    on the 2013 Capstone Project titled, “The effect of high-protein energy
    supplementation on disease progression among non-malnourished HIV-infected
    children 1-5 years old in resource limited settings”, Dartmouth College,
    Hanover, NH
    PhD Candidate 2020 (Karolinska Institutet, Stockholm, Sweden) MPH 2013
    (Geisel School of Medicine at Dartmouth, Hanover, USA) MD 2009 (Muhimbili
    University, Dar es Salaam, Tanzania)


  • The World Health Organization (WHO)'s Option B+, entailing provision of
    lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding
    women, has become the mainstay intervention for prevention of mother to child
    transmission of HIV (PMTCT) globally. This was in part motivated by
    compelling evidence from clinical trials on it's success in PMTCT . My PhD
    research is focused on answering three main questions: 1) How well does
    Option B+ work in routine care settings? 2) What influences it's success in
    these settings? 3) How can we optimize Option B+ service delivery to achieve
    maximum benefits from it? The research is based in Dar es Salaam, Tanzania


News from KI

Events from KI